AP24534 hydrochloride Datasheet DC Chemicals

Description	Ponatinib, also known as AP24534 is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. Ponatinib was approved in 2012.
Cat.No	DC31161
Name	AP24534 hydrochloride

Chemical Properties

CAS	1114544-31-8
Formula	C29H28CLF3N6O
MW	569.02
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

References

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com